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Abstract
Lactation-induced bone loss occurs due to high calcium requirements for fetal growth 
but skeletal recovery is normally achieved promptly postweaning. Dietary protein is 
vital for fetus and mother but the effects of protein undernutrition on the maternal 
skeleton and skeletal muscles are largely unknown. We used mouse dams fed with 
normal (N, 20%) or low (L, 8%) protein diet during gestation and lactation and main-
tained on the same diets (NN, LL) or switched from low to normal (LN) during a 28 
d skeletal restoration period post lactation. Skeletal muscle morphology and neuro-
muscular junction integrity was not different between any of the groups. However, 
dams fed the low protein diet showed extensive bone loss by the end of lactation, 
followed by full skeletal recovery in NN dams, partial recovery in LN and poor bone 
recovery in LL dams. Primary osteoblasts from low protein diet fed mice showed 
decreased in vitro bone formation and decreased osteogenic marker gene expression; 
promoter methylation analysis by pyrosequencing showed no differences in Bmpr1a, 
Ptch1, Sirt1, Osx, and Igf1r osteoregulators, while miR-26a, -34a, and -125b expres-
sion was found altered in low protein fed mice. Therefore, normal protein diet is 
indispensable for maternal musculoskeletal health during the reproductive period.
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1 |  INTRODUCTION
Gestation and lactation are two of the most metabolically 
challenging life phases in females, affecting almost all 
the physiological systems in the human body. Bone loss 
arises very rapidly as a result of substantial changes in the 
maternal skeleton.1 During pregnancy, fetal requirements 
for calcium are met by a twofold upregulation of intesti-
nal absorption and is thought to be the major mechanism 
of maternal adaptation, partly mediated by the action of 
1,25-vitamin D on intestinal cells.2 This environment al-
lows the maternal skeleton to accumulate sufficient cal-
cium to support bone mineralization in the fetus during the 
third trimester.3 Maternal bone mass declines during lacta-
tion, when skeletal calcium is released to the breast milk. 
Although renal calcium excretion is reduced with increased 
tubular reabsorption,1 this is not sufficient to prevent bone 
loss. Increased circulating parathyroid hormone-related 
peptide (PTHrP), produced by the lactating breast, plays 
a key role in calcium release and in combination with low 
estradiol levels leads to high bone resorption rates.4
Breast-feeding milk from lactating dams is the main 
source of food for the neonates and the maternal skeleton pro-
vides a large proportion of calcium that is vital for the grow-
ing newborn skeletal system.5,6 The overall bone turnover is 
increased during lactation, but bone resorption exceeds for-
mation and this leads to substantial bone mass reduction.7,8 
Studies in humans have shown that women's bone loss can 
reach around 7%, while this percentage in female mice is 
greater (up to 30%) due to higher numbers of offspring being 
suckled during the 3-week lactation period.9,10 However, 
weaning triggers skeletal recovery that occurs very rapidly 
after the end of lactation.10,11 Bone mass regain is mediated 
by increased apoptosis of resorptive osteoclasts and increased 
rates of bone formation10,11 with partial or full restoration of 
mechanical properties.12 Although epidemiological studies 
in humans suggest that the number of pregnancies has no 
long-term effects on fracture risk,13,14 data for the duration of 
lactation are controversial and some studies report that there 
is a possible correlation with lower bone mineral density 
(BMD) in later life.15,16 It has also been suggested that BMD 
is fully recovered at the lumbar spine but only partially at 
the hip in humans17,18 and in the tibia in rodents.19 However, 
the detailed molecular mechanisms and signaling pathways 
that regulate postweaning maternal bone recovery are largely 
unknown.
Protein metabolism is also challenging especially during 
lactation, when nutrient enriched milk production has to be 
sufficient for the newborn. Protein catabolic rates are in-
creased dramatically and maternal body protein reservoirs, 
such as the skeletal muscles, are recruited to meet these re-
quirements.20 Protein mobilization from skeletal muscle is 
triggered as an adaptive response to enhance protein content 
in milk through proteolysis and this process is in fine bal-
ance with maternal dietary protein intake.21,22 Muscle met-
abolic events, such as fatty acid oxidation, are also linked to 
food intake via nervous system mediated regulation.22 To our 
knowledge, while muscle proteolysis has been largely stud-
ied during lactation, there is no evidence for maternal skel-
etal muscle fiber morphological changes or neuromuscular 
junctions (NMJs), the synapse between a motor neuron and 
a muscle fiber, in conjunction with protein under-nutrition.
Dietary calcium (Ca) and vitamin D supplements during 
gestation and lactation have been extensively studied, sug-
gesting beneficial effects on both maternal and fetal/offspring 
skeletal homeostasis.23 Ca supplementation in the maternal 
diet has been proved beneficial for both maternal and off-
spring bone health24; the National Academy of Sciences rec-
ommends 1000 mg of daily Ca consumption for pregnant and 
breastfeeding women. Although some studies have explored 
the consequences of other nutrients, such as soy isoflavone25 
and prebiotics26 on the maternal skeleton and other organs 
during lactation and recovery, very little is known about the 
effects of the maternal protein intake.
In recent years, there has been increasing evidence of the 
epigenetic regulation of bone health. Epigenetic mechanisms 
are potential therapeutic targets due to their reversible na-
ture. Several studies have suggested that methylome changes 
play an important role in osteoblast differentiation and activ-
ity.27-30 Hypomethylation of the promoters of the runt-related 
transcription factor-2 (Runx-2), bone gamma-carboxygluta-
mate protein (Bglap, the coding gene for osteocalcin), and os-
terix (Osx) genes is involved in osteogenic differentiation of 
adipose-derived mesenchymal stromal cells (MSCs).31 Other 
regulatory mechanisms involve microRNAs (miRs) that can 
regulate posttranscriptional gene expression. MiRs have 
been shown to control bone-related genes.32-34 For example, 
miR-204/211 levels are increased, suppressing Runx-2 gene 
expression and promoting adipogenic over osteogenic differ-
entiation of mesenchymal stromal cells (MSCs),34 while miR-
15b induces osteoblast differentiation by inhibiting Runx-2 
degradation.35 Moreover, overexpression of miR-2861 and 
miR-3960 promotes BMP2-induced osteoblastogenesis, and 
their suppression inhibits osteoblast differentiation.36 It is 
also known that miRs are essential for endochondral ossifica-
tion since osteoblast-specific Dicer knockout mice have defi-
cient cortical bone formation and bone integrity.37,38
The aim of this study was to investigate the effects of 
protein restriction on the maternal musculoskeletal system 
in mouse dams during gestation and lactation as well as 
the postweaning recovery period. Histological structural 
measurements in skeletal muscle and NMJ morphology 
evaluations were performed. Bone microarchitecture and 
turnover were assessed using micro computed tomography 
(microCT) and bone histomorphometry. In vitro exper-
iments on primary bone cells and expression patterns of 
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selected miRs were investigated to determine whether an 
epigenetic event may be associated with maternal skeletal 
recovery delay.
2 |  MATERIALS AND METHODS
2.1 | Animals
This study included 39 female mice. We used B6.Cg-
Tg(Thy1-YFP)16Jrs/J mice, which express yellow fluo-
rescent protein (YFP) only in neuronal cells (Jackson 
Laboratory; stock number 003709). Mice were housed in in-
dividually vented cages maintained at 21 ± 2°C on a 12-hour 
light/dark cycle. All experimental protocols were performed 
in compliance with the UK Animals (Scientific Procedures) 
Act 1986 regulations for the handling and use of laboratory 
animals and received ethical approval from the University 
of Liverpool Animal Welfare Ethical Review Committee 
(AWERB). Mice were monitored daily for any health and 
welfare issues.
2.2 | Experimental groups
All mice were fed ad libitum food and water. Solid food pel-
lets of normal protein diet (N, 20% crude protein; Special 
Diet Services, UK; code 824226) or low protein diet (L, 8% 
crude protein; Special Diet Services, UK; code 824248) were 
of isocaloric value. Groups of 8 weeks old nulliparous female 
mice were fed on either L (low) or N (control) protein diet for 
2 weeks prior to mating. Once adapted to the diets, the mice 
were mated with age-matched males on N diet and the preg-
nant mice were kept on the same diet throughout gestation (19-
21  days) and lactation (21  days). Suckling pup number was 
kept the same for all animals during lactation (n = 5-6 pups) 
to prevent confounding effects of differences in litter size. 
Following lactation, mice in the normal (group Lac-N, n = 8) 
F I G U R E  1  Experimental design of the study (A). Total body weights of the mouse dams used in all experimental groups (B) and the 
corresponding tibial and L5 vertebral length as measured by microCT showing no difference between the groups (C). The net weights of TA 
and EDL skeletal muscles were similar in Lac-N (n = 8) and Lac-L (n = 8) mice when compared to Virgins control (D) and image analysis of 
transverse cryosections (E) showed no changes in the fiber morphology and fiber CSA in the TA muscles (F). Similarly, NMJs appeared unaffected 
with perfect overlapping of the presynaptic (green) and postsynaptic (red) terminals (G). All data are presented as mean ± SD. ns: not significant; 
***P < .001; scale bar: 100 μm
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and low (group Lac-L, n = 8) groups were culled (16 weeks 
old) and tissues were harvested (skeletal muscles and bones). 
The recovery (Rec) groups were comprised of dams (20 weeks 
old) fed on N until the end of lactation and remained on the 
same diet for the recovery (28 days) period (group Rec-NN, 
n = 5), and mice on L diet until weaning, which remained on 
the same diet for recovery (group Rec-LL, n = 5) or switched 
postweaning to N protein diet (group Rec-LN, n = 5) for the 
recovery period (Figure 1A). At the end of lactation or recovery 
mice were euthanized by a rising concentration of CO2. Age-
matched virgin mice (18  weeks old) were used as a control 
(group Virgins, n = 8). To reduce the number of animals ac-
cording to 3Rs recommendations, the end-point age of Virgins 
was kept at the middle of the recovery period (2 weeks after lac-
tation and 2 weeks before recovery end) to serve as controls for 
both experimental periods (Figure 1A). At least for the skeletal 
system, no significant change has been observed in bone mass 
and structure of female mice between months 3-4 of age.39
2.3 | Muscle histology and NMJ imaging
2.3.1 | Skeletal muscles
Immediately after culling, the extensor digitorum longus (EDL) 
and tibialis anterior (TA) skeletal muscles were carefully dis-
sected and weighed (n = 5). The TA muscles were embedded 
in Cryomatrix (Thermo Fischer, UK), immediately immersed 
in liquid nitrogen-frozen isopentane, and stored at −80°C for 
cryosectioning. TA muscles were placed at −20°C for at least 
30 minutes prior to cryosectioning. Transverse sections (10 μm) 
were cut using a Leica cryotome and collected on Superfrost 
glass slides (ThermoScientific, UK). Sections were washed 
with PBS for 10 minutes before staining with 1:1000 dilution 
of rhodamine wheat germ agglutinin (WGA; 5 μg/mL;Vector 
Laboratories, UK) for 10 minutes, mounted in antifade medium 
with DAPI (Vector Laboratories, CA, USA), and were visual-
ized with an Axio Scan.Z1 slide scanner (Zeiss, UK).
The EDL muscles were fixed in 10% of neutral-buffered 
formalin (NBF) and stored in PBS with sodium azide at 4°C 
for NMJs morphological image analysis. Before staining, 
samples were washed in PBS for 5 minutes, and then, stained 
with α-Bungarotoxin-Alexa Fluor 647 conjugate (Invitrogen, 
UK) diluted 1:500 in PBS for at least 30 minutes in a dark en-
vironment at room temperature. Muscles were kept in a dark 
environment until analysis on a Nikon C1 Eclipse Ti confocal 
laser scanning microscope (Nikon, UK).
2.3.2 | Bones
The spines and left or right hindlimbs were dissected, cleaned 
from muscles, fixed in 10% of NBF solution for 24 hours, 
extensively washed with PBS and scanned with microCT, 
followed by decalcification in 10% of EDTA for 3  weeks 
and subsequent storage in 70% of EtOH until processing 
(n = 5-8). The other hindlimb was used for primary osteo-
blasts (Obs) isolation and cell cultures. Decalcified spines 
were embedded in paraffin or cryopreserved and embedded 
in Cryomatrix and sectioned coronally (5-8  μm thickness). 
H&E staining was performed using standard protocol and 
tartrate-resistant acid phosphatase (TRAP) as previously de-
scribed.40 Osteoblasts were identified by their cuboidal shape 
and proximity to endosteal surfaces and osteoclasts by their 
red color after TRAP staining. For IHC experiments, cryo-
sections were washed with PBS, blocked with 10% of normal 
goat serum (NGS) and nonimmune rabbit serum served as a 
negative control. Rabbit anti-mouse osteocalcin (Ocn) poly-
clonal antibody (Abcam, UK, ab39876) was used in 1:500 
dilution in 5% of NGS to identify osteoblasts. Primary anti-
bodies were detected using a Vectastain ABC kit with a sec-
ondary goat anti-rabbit-biotinylated antibody and visualized 
with HRP-conjugated streptavidin using 3,3′-diaminobenzi-
dine (DAB; Vectorlabs, UK). Histomorphometric analyses 
were performed according to ASBMR standards using open-
source software.40,41
2.4 | Micro-computed tomography
Hindlimbs and L5 lumbar vertebra were scanned using a 
Skyscan 1272 scanner (Bruker, Belgium; 0.5 aluminum fil-
ter, 50 kV, 200 mA, voxel size 4.60 μm, 0.3° rotation angle 
step). Data sets were reconstructed using NRecon and 3D 
volumes of interest (VOI) were selected using Dataviewer 
and CTAn software (Bruker, Belgium). Trabecular bone pa-
rameters were analyzed using CTAn in the proximal tibial 
metaphysis and the vertebral body of L5 vertebra. Cortical 
bone was analyzed at the tibial midshaft. For trabecular bone 
analysis, VOI was selected using mineralized cartilage as a 
reference point. The tibial VOI analyzed was 400 slices start-
ing 20 levels distal to the reference point, while for corti-
cal bone measurements, a VOI (100 slices) was selected 600 
slices below the reference point, as previously described.42,43 
Trabecular bone was automatically separated from cortical 
bone using a macro in CTAn.
2.5 | In vitro bone cell culture and 
mineralization assay
For the primary bone cell cultures, immediately after microCT 
scans (<2 hours from sacrifice), midshafts of long bones were 
isolated (n = 3/group), surrounding muscles removed, and the 
bones centrifuged (3  minutes at 800  g) to remove the bone 
marrow. The bone shafts were cut into small pieces using a 
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scalpel and adhering cells were removed by digestion with col-
lagenase type I (Sigma, 1 mg/mL in Hank's balanced salt solu-
tion, HBSS) for 45 minutes in a shaking water bath at 37˚C, 
washed in PBS, and cultured in alpha-MEM with Glutamax 
(Gibco, UK) and nucleosides, containing 10% of heat-inacti-
vated FBS and penicillin (100 IU/mL)/streptomycin (100 μg/
mL) (Invitrogen) in a humidified 5% of CO2 incubator at 37°C, 
as previously described.42 Upon reaching semi-confluence, 
Obs grown out of the cleaned bone chips, were harvested using 
trypsin/EDTA (Gibco, UK) and seeded onto 6-well plates (105 
cells/well) in osteogenic medium (50 μg/mL L-ascorbic acid-
2-phosphate and 5 mM β-glycerophosphate) (Sigma, UK) for 
24 days. Mineralization capacity was assessed by Alizarin Red 
S (ARS) (Sigma, UK) staining. Bone nodule surface area was 
calculated using ImageJ (NIH), as previously described.42,44
2.6 | Quantitative polymerase chain reaction
To assess gene expression levels, total RNA was isolated 
from Obs at the end of mineralization (24 d) using TRiZOL 
reagent (Invitrogen, CA, USA), cleaned-up using the RNeasy 
kit (Qiagen, UK) and cDNA was synthesized with the High 
Capacity cDNA Transcription kit (Applied Biosystems, UK). 
Expression levels of alkaline phosphatase (Alp), collagen type 
1 (Col1a1), Runx-2, and Bglap mRNA were used as osteo-
genic markers42 (Table S1). Quantitative polymerase chain re-
action (qPCR) was performed on a RotorGene 6000 (Corbett 
Research) instrument with SYBR (Bioline, UK) and results 
were analyzed using beta-actin (Actb) as a stable reference gene 
for osteoblasts.45 For miR expression analysis at the 24 d cell 
culture end-point, total RNA (n = 3/group) was isolated and pu-
rified using the mirVana kit (Thermo Fisher, UK), reverse tran-
scription of total RNA containing miRs was performed with 
miScript II RT kit (Qiagen, UK) and specific primers for miR-
26a, 34a, and -125b were used for the qPCR utilizing RNU6 as 
the reference gene. Results were analyzed using the modified 
delta CT method46 or presented as fold difference as compared 
to the reference gene levels.
2.7 | miR:target prediction and 
bioinformatics
To predict the targets of the differentially expressed miRs, 
we used the miRWalk on-line tool47 by applying simulta-
neous search from four different databases, including miR-
Walk, TargetScan,48 miRDB,49 and MiRTarBase50 using 
the default parameters of 7 as the minimum seed length at 
the 3′-UTR site and showing only the statistically signifi-
cant mRNAs. A total of 174 target genes were obtained. 
Cytoscape v3.7.251 software was used to build the interaction 
networks between predicted targets and miRs as well as to 
determine the biological roles of the target mRNAs utilizing 
Gene Ontology (GO) terms of biological process and mo-
lecular functions. The enriched GO terms were presented as 
enrichment scores. KEGG pathway analysis52 was performed 
to determine the involvement of the predicted mRNAs tar-
gets in different biological pathways. P < .05 was considered 
to indicate a statistically significant result.
2.8 | Promoter methylation analysis
Pyrosequencing methylation assays for bone morphogenetic 
protein receptor 1a (Bmpr1a), patched 1 (Ptch1), osterix 
(Osx), insulin-like growth factor 1 receptor (Igf1r), and sirtuin 
1 (Sirt1) gene promoters were designed using the Pyromark 
Assay Design 2.0 software (Qiagen). PCR and sequencing 
primers are provided in Table S1. Osteoblasts-derived genomic 
DNA (1  μg each) from all the experimental groups (n  =  3/
group) was subjected to bisulfite treatment using the EZ DNA 
methylation kit (Zymo Research, USA) according to the manu-
facturer's protocol. Pyrosequencing templates were prepared by 
PCR amplification (45 cycles) of approximately 30 ng bisulfite-
treated DNA using HotStarTaq Master Mix (Qiagen), 150 nM 
biotinylated primer, and 300  nM nonbiotinylated primer 
(Table S1). Optimized annealing temperatures were 52°C for 
Bmpr1a, 51°C for Ptch1, 48°C for Sirt1, 50°C for Osx, and 
55°C for Igf1r. PCR efficiency and specificity were verified by 
agarose gel electrophoresis. PCR products were immobilized 
on streptavidin coated sepharose beads, and pyrosequenced on 
PyroMark Q96 MD instrument (Qiagen) according to the man-
ufacturer's instructions. The sequence runs were analyzed using 
the Pyromark Q962.5.8 software Q-CpG software.
2.9 | Statistical analysis
All data were analyzed with GraphPad Prism 6 software 
and expressed as the mean ± SD. Data sets were tested for 
normal distribution with the D'Agostino-Pearson normality 
test. Comparisons between four groups were performed by 
one-way analysis of variance (ANOVA) followed by Tukey's 
multiple comparisons post hoc test where appropriate. For 
comparisons between two groups, unpaired Student's t test or 
Mann-Whitney U test was applied. In all cases, P values less 
than .05 were considered statistically significant.
3 |  RESULTS
3.1 | Body weights and bone length
Total body weights were recorded after euthanasia. There was 
no difference between groups Lac-N and Lac-L (16 weeks 
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old) while weight was increased in both these groups com-
pared to the Virgins group (18  weeks old), as expected 
(Figure 1B). For the recovery period, similar weights were 
observed for all groups of animals (Rec-NN, Rec-LN and 
Rec-LL) (Figure 1B). Additionally, there was no difference 
in tibial and L5 vertebral lengths, as measured by microCT 
(Figure 1C).
3.2 | Low protein diet has no effect on 
skeletal muscle and NMJ morphology in 
mouse dams
We first examined the effects of low protein diet during 
pregnancy and lactation on skeletal muscle and NMJ mor-
phology. There was no difference in TA and EDL weights 
between the Virgins, Lan-N, and Lac-L groups (Figure 1D). 
Furthermore, cross-sectional area (CSA) of the TA skel-
etal muscle fibers, measured using transverse cryosections, 
was also similar between groups (Figure  1E,F). Detailed 
confocal image analysis of the EDL muscle also indicated 
that NMJ morphology was not affected by the reproduction 
process or the protein content of the diet, as the presyn-
aptic YFP-labeled motor axons and the postsynaptic bun-
garotoxin-stained AchRs perfectly overlapped without any 
evidence of denervation or clustering (Figure 1G). In light 
of these findings, we decided not to proceed with muscle 
and NMJ analyses for the recovery groups.
3.3 | Protein under-nutrition enhances 
lactation-induced bone loss and delays recovery
We evaluated the effect of low protein intake on tibial and L5 
vertebral bone mass by measuring the trabecular and cortical 
parameters obtained from microCT scans. Our aim was to 
first examine if protein under-nutrition during gestation and 
lactation had an impact on skeletal mass and structure and if 
so, how this diet would affect bone recovery. Therefore, we 
compared the trabecular %BV/TV in tibiae between Lac-N 
and Lac-L dams, without using controls as the lactation-
induced bone loss has been extensively been reported in 
rodents.10,11 Lac-L dams had a significant reduced bone vol-
ume in comparison with lactating Lac-N mice on a normal 
diet, due to decreased trabecular thickness, and decreased tra-
becular number as well as decreased connectivity and a more 
rod-like appearance of the trabecular bone (Figure  2A,G, 
Table S2), reflecting a compromised bone microarchitecture. 
Similar outcomes were obtained for the trabecular network in 
L5 vertebral body, showing a further bone mass reduction of 
22.75% in Lac-L as compared to Lac-N mice (Figure 2E,K, 
Table S2). Cortical bone analyses revealed a significant de-
crease in the cortical thickness in the midshaft of long-bones 
in lactating mice with greater thickness loss in the Lac-L 
group, in comparison with Lac-N (Figure 2C,H).
After weaning, female mice in the Rec-NN group, which 
were fed a normal protein diet during gestation and lactation 
as well as for the recovery period of 28 d, showed full re-
covery of trabecular bone volume and architecture in tibiae 
(Figure 2B,I, Table S2) and in L5 vertebrae (Figure 2F and 
L, Table S2), when compared to the Virgins group. Rec-NN 
mice had statistically significant higher trabecular bone vol-
ume than Rec-LN and Rec-LL mice, at both skeletal sites. 
Cortical bone thickness showed full recovery in the Rec-NN 
group, partial recovery in the Rec-LN and poor recovery in 
the Rec-LL (Figure 2D,J).
3.4 | Low protein intake has detrimental 
effects on bone remodeling
In order to evaluate bone turnover in the spines of mouse 
dams, we performed bone histomorphometric analyses, as 
previously described.40 Routine H&E staining (Figure S1), 
confirmed by Ocn IHC (Figure 3A), showed that Lac-L lactat-
ing dams had lower numbers of osteoblasts per bone surface 
(NOb/BS) and reduced osteoblastic surface per bone surface 
(ObS/BS) as compared to the Lac-N group (Figure 3B,C). In 
the recovery period, Rec-NN mice showed increased osteo-
blast numbers, in comparison with the Virgin control mice. 
In contrast, osteoblastic number and surface was lower in 
the Rec-LN mice while the Rec-LL mice showed no signs of 
recovery with significantly reduced osteoblast number and 
surface (Figure 3D-F).
TRAcP staining revealed that lactating mice on the low 
protein diet had increased osteoclast numbers and size com-
pared to the Lac-N group (Figure  4A). Osteoclast number 
and size were also increased in the Rec-NN dams compared 
to the Virgin controls (Figure 4B,C), indicating a high rate of 
bone remodeling, most likely coupled with increased bone 
formation. Interestingly, Rec-LN mice showed increased 
osteoclastic activity compared to the Virgins but not to the 
Rec-NN group. On the contrary, maintenance on low protein 
diet during the recovery period resulted in higher numbers of 
bone-resorbing cells when compared to control and Rec-NN 
mice (Figure 4D-F).
3.5 | Low protein diet reduces in vitro 
bone formation
The next sets of experiments were designed to assess the os-
teogenic capacity of osteoblasts in vitro. Obs were isolated 
from long-bones of animals of all six groups (n = 3/group) 
and the level of mineralization using ARS staining was evalu-
ated after 24 days of culture in osteogenic medium. We found 
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that the mineralization level was correlated with the level of 
protein in the diet that the mice consumed by the end of lacta-
tion. Osteoblasts isolated from Lac-N lactating dams formed 
larger and more numerous bone nodules as compared to the 
Lac-L group (Figure  5A,C). Furthermore, mRNA expres-
sion levels of Alp, the master osteogenic transcription factor 
Runx-2, as well as Bglap, and Col1a1, were all decreased in 
the Lac-L in comparison with Lac-N (Figure 5E,F,I,J), indi-
cating decreased osteoblastic differentiation and activity.
In the recovery period, Obs from the Rec-NN group 
formed a significantly increased number of mineralized bone 
nodules compared with Virgins and also with Rec-LN and 
Rec-LL, in agreement with the histological as well as the 
microCT observations (Figure  5B,D). Interestingly, mRNA 
levels of Alp, Col1a1, Bglap, and Runx-2, reflecting osteo-
genic differentiation and activity, were found increased in the 
Rec-NN group, and suppressed predominantly in the Rec-LL 
group (Figure 5G,H,K,L).
3.6 | DNA methylation analysis
To identify potential epigenetic mediators of these effects, 
we performed targeted pyrosequencing for DNA meth-
ylation analysis of the promoters for the Bmpr1a, Ptch1, 
Sirt1, Osx, and Igf1r genes, while Runx-2, Alp, Col1a1, 
F I G U R E  2  Representative images and quantitative comparisons in Lac-N (n = 8) and Lac-L (n = 8) mouse dams during gestation/lactation 
for tibial trabeculae %BV/TV (A and G), cortical thickness (C and H) and the L5 trabecular %BV/TV (E and K). Tibiae and spines of Rec-NN, 
Rec-LN and Rec-LL mice (n = 5/group) were collected after the 28 d recovery and compared to the control Virgins (n = 8) group (B and I for tibial 
trabecular %BV/TV; D and J for cortical thickness; F and L for L5 trabecular %BV/TV). All data are presented as mean ± SD. ns: not significant; 
&&P < .01, &&&P < .001, &&&&P < .0001 in Lac-N versus Lac-L comparisons. Asterisks indicate comparisons versus Virgins and crosses versus 
Rec-NN
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and Bglap were only used as osteogenic markers. The ex-
pression patterns of these genes are known to be affected 
by diet.53-57 They are also considered as crucial molecular 
players in the major signaling pathways that control osteo-
blastic differentiation and activity: Bmpr1a in BMP path-
way, Ptch1 in hedgehog pathway, Igf1r in IGF signaling, 
while Osx is a master regulator of osteoblast differentia-
tion and Sirt1 links nutritional diet with bone formation.58 
All the samples demonstrated negligible DNA methyla-
tion, consistent with the promoters being in the active 
state, with signal ranging within the established noise area 
of the technology.59 Representative pyrograms are given 
in Figure S2.
3.7 | Differential expression of specific miRs 
may regulate bone recovery delay induced by 
low protein diet
Based on the in vitro results, we hypothesized that the 
delay of bone recovery in the Rec-LL and, partially, in the 
Rec-LN group might be caused by differential expression 
(DE) of bone-related miRs. It has been shown that, among 
others, some miRs were directly related with bone metabo-
lism. For example, miR-26a regulates osteogenic differen-
tiation of BMSCs and ADSCs by differentially activating 
Wnt and BMP signaling pathways.60 Furthermore, it has 
been shown that miR-26a attenuates osteoclastogenesis, 
F I G U R E  3  Representative Ocn (A) immunostained L5 vertebral body sections and quantitative comparisons in Lac-N (n = 5) and Lac-L 
(n = 5) mouse dams during gestation/lactation for number of osteoblasts per bone surface (N.Ob./BS) (B) and the percentage of osteoblast surface 
per bone surface (Ob.S./BS) (C). The corresponding histological images and parameters for the recovery period in Rec-NN (n = 5), Rec-LN 
(n = 5) and Rec-LL (n = 5) groups are shown in D, E, and F, respectively, and were compared to the Virgins control. Arrows indicate Ocn-positive 
osteoblasts attached to the bone surface. All data are presented as mean ± SD. ns: not significant; &P < .05, &&P < .01 in Lac-N versus Lac-L 
comparisons. Asterisks indicate comparisons versus Virgins and crosses versus Rec-NN. *P < .05, **P < .01, ***P < .001, ****P < .0001
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actin-ring formation, and bone resorption by suppressing 
the expression of connective tissue growth factor/CCN 
family 2 (CTGF/CCN2)61; miR-34a is downregulated 
during osteoclast differentiation62 and miR-125b controls 
the osteogenic differentiation of hBMSCs by targeting 
BMPR1b63 and also inhibits BMP-4-induced osteoblastic 
differentiation by regulating cell proliferation in mouse 
ST2 MSCs, via targeting of the receptor tyrosine kinase 
Erb2.64 Therefore, we selected these three miRs, -26a, 34a, 
and 125b, which according to the literature have direct ef-
fects on osteoblastic differentiation,60,62,63 and performed 
qPCR to determine their expression levels in Obs isolated 
from the mouse groups used for the bone recovery period. 
The levels of miR-26a were found slightly increased in 
the Rec-NN group as compared to the Virgins and signifi-
cantly suppressed in the Rec-LN and Rec-LL mice. The 
endogenous expression of miR-26a is increased during the 
osteogenic differentiation,65 thus, the suppressed levels in 
Rec-LN and Rec-LL are consistent with decreased osteo-
genesis. We also found that miR-34a was downregulated in 
the Rec-LN and Rec-LL and in-keeping with previous stud-
ies reporting that miR-34a-overexpressing transgenic mice 
exhibit lower bone resorption and higher bone mass through 
transforming growth factor-β-induced factor 2 (Tgif2) in-
hibition,62 it is revealed that miR-34a is important for bone 
regulation. The levels of miR-125b followed the opposite 
pattern and were elevated in the low bone-forming capac-
ity Obs from the Rec-LN and Rec-LL dams in comparison 
F I G U R E  4  Osteoclastic TRAcP was visualized in Lac-N and Lac-L dams during gestation/lactation (A) and quantified using the number 
of osteoclasts per bone surface (N.Oc./BS) (B) and the percentage of osteoclast surface per bone surface (Oc.S/BS) (C) parameters. Similarly, 
representative images (D) and data comparisons (E and F) are shown for the recovery period against Virgins. Arrows indicate TRAcP-positive 
osteoclasts attached to the bone surface. All data are presented as mean ± SD. ns: not significant; &P < .05, &&P < .01 in Lac-N versus Lac-L 
comparisons. Asterisks indicate comparisons versus Virgins and crosses versus Rec-NN. *P < .05, **P < .01, ***P < .001, ****P < .0001
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with the Rec-NN and Virgins groups (Figure 6A). This was 
the most important miR that we measured as it directly in-
hibits Runx-266 and suppresses bone formation by repress-
ing Wnt/β-catenin negative regulators67 and is directly 
linked to our findings for decreased expression levels of 
Runx-2 in the Rec-LL group (Figure 5).
Using the DE of these specific miRs, bioinformatic 
analyses revealed a total of 174 genes predicted as potential 
targets, while 18 genes were common (Figure 6B, enlarge-
ment in Figure S3). Statistically significant biomolecular 
interactions, using constructed networks of GO and KEGG 
pathways, showed that, among others, some important 
bone regulatory mechanisms and biological processes can 
be affected, namely the Wnt and IL-6 signaling pathways, 
thyroid hormone synthesis, mesenchymal cell differentia-
tion, and negative regulation of ERK1 and ERK2 cascades 
(Figure  6C, enlargement in Figure S4). Finally, it was 
found that the vast majority of the implicated gene targets 
(69.57%) were involved in Wnt signaling and pluripotency 
(Figure 6D).
F I G U R E  5  Primary bone-forming cells form all the experimental group (n = 3/group) were isolated and cultured in osteogenic medium for 
4 weeks. Alizarin Res S (ARS) staining (A) was used and quantified (C) for bone mineralization evaluation and Alp (E), Runx-2 (F), Bglap (I), and 
Col1a1 (J) gene expression was measured by qPCR to assess osteogenic capacity in Lac-N and Lac-L mouse dams during gestation/lactation. The 
corresponding ARS stained bone nodules, ARS quantification and gene expression levels for the recovery period in Rec-NN, Rec-LN, and Rec-LL 
groups are shown in B, D, G, H, K, and L, respectively, and were compared to the Virgins control. All data are presented as mean ± SD. ns: not 
significant; &P < .05, &&P < .01 in Lac-N versus Lac-L comparisons. Asterisks indicate comparisons versus Virgins and crosses versus Rec-NN. 
*P < .05, **P < .01, ***P < .001, ****P < .0001
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4 |  DISCUSSION
In this study, we report that protein under-nutrition during 
gestation/lactation and recovery periods reproduction exerts 
detrimental effects on the skeletal system of mouse dams and 
decreases the rate of bone accretion in the postweaning re-
covery period. We also examined the effects of low protein 
intake during gestation and lactation on skeletal muscle in-
tegrity as well as on NMJ morphology and importantly report 
for the first time in the literature that there were no differ-
ences when compared with normal protein consumption.
Our first aim was to explore if a low protein diet during 
gestation and lactation can affect skeletal muscles. Lactation 
is linked to significant changes in maternal metabolism 
and subsequent adaptations, such as decreased adaptive 
thermogenesis, are necessary due to high-energy demands 
for sufficient milk production.68,69 Liver, skeletal muscle 
and white adipose tissue are the main metabolic tissues in 
mammals,70 and thus, their metabolic rates are modulated 
during lactation. Skeletal muscle protein mobilization acts as 
an adaptive response to meet these energy requirements and 
is also finely regulated in proportion to the dietary protein 
intake. In our cohort of mouse dams, no significant change 
in the TA skeletal muscle fiber CSA was observed, possibly 
due to activation of other metabolic pathways aiming to fulfil 
energy demands since both experimental diets (normal and 
low protein) were isocaloric. Maternal protein loss during 
lactation is decreased when total body protein mass10,11 ex-
ceeds certain levels to prevent exhaustion.71 Similarly, no 
differences were observed in NMJ morphology and structure 
F I G U R E  6  Differential expressions (DE) of miR-26a, 34a and-125b (A) in Rec-NN, Rec-LN, and Rec-LL groups are shown for the recovery 
period and were compared to the Virgins control (n = 3/group). Using bioinformatics, the predicted target genes were mapped (B) and biomolecular 
interactions were designed by gene ontology (GO) and KEGG pathways analyses (C). Wnt signaling seems to be the dominant pathway affected by 
the selected miRs among the statistically significant regulatory mechanisms (D). All data are presented as mean ± SD. ns: not significant. Asterisks 
indicate comparisons versus Virgins and crosses versus Rec-NN. *P < .05, **P < .01, ***P < .001
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between Virgins, Lac-N, and Lac-L groups, supporting our 
findings that low protein intake during gestation and lactation 
does not dramatically alter skeletal muscles as these two sys-
tems function integrally.
Our second aim was to determine changes in the skele-
ton of mouse dams due to low protein diet during gestation 
and lactation. Pregnancy and lactation are very challenging 
periods for the maternal skeleton due to significant adjust-
ments in calcium homeostasis. Our study showed that lac-
tation resulted in a significant decrease of bone volume and 
deterioration of bone micro-architecture in both trabecular 
and cortical bone. It is known that lactation causes deminer-
alization of the maternal skeleton, which leads to bone mass 
reduction.72 BV/TV was significantly reduced in the proxi-
mal tibia and L5 vertebral body, and this was accompanied 
by thinning of the trabeculae at both skeletal sites. Cortical 
bone thickness at the tibial mid-diaphysis was also consid-
erably decreased by lactation. These changes were exacer-
bated in the Lac-L mouse dams indicating that low protein 
consumption leads to more profound skeletal deterioration 
than normal protein consumption during the reproductive 
period. Although some studies have reported that the extend 
of lactation-induced bone loss is different according to the 
anatomical site of the skeleton and is, particularly, higher in 
the spine than in the long-bones,19 our model did not identify 
any differences showing a universal effect on both sites. An 
important finding was that all microCT structural parame-
ters were worsened in the Lac-L group as compared to Lac-
N, and the changes in SMI and Tb.N show that low protein 
diet affects not only the overall bone mass, but also leads to 
micro-architectural changes. The increased SMI shows that 
the shape of trabeculae has altered from plate-like to a more 
rod-like structure, similar to other studies.73 However, these 
studies have significant differences from the present study, 
that is, mouse strain and larger litter size. Histomorphometric 
analyses of animal models have shown that bone turnover is 
increased during pregnancy74 and these high rates of bone 
formation and resorption are maintained throughout lacta-
tion. Our results indicate that mouse dams fed a normal diet 
during gestation and lactation, Lac-N, follow this trend but, 
on the contrary, the Lac-L mice show suppressed numbers 
of osteoblasts, and very high levels of osteoclastic bone re-
sorption. Thus, the overall result is a significant bone loss as 
compared to the Lac-N group, and this is supported by the 
results of the microCT analysis. Our in vitro findings support 
our hypothesis that enhanced bone loss in the Lac-L mice 
was caused, at least partly, by the substantially reduced os-
teogenic capacity of the osteoblasts that was coupled with 
decreased expression of osteogenic genes in comparison with 
the Lac-N group. Dietary protein has beneficial effects on 
bone health,75 but very little is known regarding lactation. On 
the contrary, several studies have shown that a high fat diet 
leads to rapid bone loss in mice76-79; however, most of the 
works used normal mice during other than gestational or lac-
tational period, in which bone and energy metabolism signifi-
cantly differ from the physiological state. The mechanisms 
that regulate lactation-related skeletal loss have been exten-
sively studied, suggesting an interplay between increased 
osteocytic osteolysis, coordination by the brain-breast-bone 
circuit through pituitary-derived prolactin and oxytocin in re-
sponse to suckling, which leads to the release of parathyroid 
hormone-related protein (PTHrP) and subsequent prolifera-
tion and activation of osteoclasts.72 However, the effects of 
protein intake on this molecular network are largely unknown 
and this needs further investigation.
Our next goal was to study the effects of low protein diet 
on the bone recovery period after weaning. Regardless of 
the accelerated bone loss that occurs during lactation, bone 
mass recovers promptly after weaning and termination of 
milk production. The recovery process is characterized by 
a sudden cessation of bone resorption and a remarkably el-
evated rate of bone formation with rapid re-mineralization 
of new bone matrix.15,80 Normally, the recovery period lasts 
approximately 6 months in humans and 4 weeks in mice and 
mineral content reaches the baseline values before pregnancy 
by gaining 2% to 3% mineral apposition per month in hu-
mans and 10% to 20% per week in mice.1,81 However, some 
studies suggest that pharmaceutical approaches such as zole-
dronate73 or osteoprotegerin82 administration can prevent 
maternal lactation-induced bone loss and improve bone re-
covery, but concerns may arise for neonatal fetal growth and 
health. We found that after 28 days from the end of lactation 
only the dams that were on the normal protein diet through-
out the entire experimental period (Rec-NN) achieved full 
recovery with microCT bone parameters that did not differ 
from the nulliparous control at any of the skeletal anatom-
ical sites. Rec-LN mice had lower bone mass compared to 
the Rec-NN group, which shows that switching from low to 
normal protein diet after weaning leads to only partial bone 
recovery. The difference between Rec-LN and Rec-LL was 
of great interest, showing that maintaining mice on a low 
protein diet leads to an extensive delay in skeletal recovery. 
Interestingly, the Rec-LL group did not differ from the Lac-L 
during lactation, showing signs of persistent failure to recu-
perate lactation-induced bone reduction.
Our results indicate that a low protein diet has deleteri-
ous effects on osteoblasts and enhances osteoclastic bone 
resorption. Elefteriou et al83 have shown that activating 
transcription factor 4 (ATF4), a transcription factor that 
enhances amino-acid uptake and collagen synthesis in os-
teoblasts, is a crucial player highlighting the significance 
of protein intake in bone formation. ATF4−/− mice showed 
a deformed skeletal phenotype that was rescued by high 
protein diet intake through an increase of collagen type I 
synthesis and osteocalcin expression by differentiated os-
teoblasts due to higher amino-acid uptake. It has also been 
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reported that protein malnutrition stimulates bone mar-
row mesenchymal stem cells differentiation to adipocytes 
rather than osteoblasts84 and attenuates the bone anabolic 
response to PTH in female rats.85,86 Therefore, we exam-
ined the behavior of isolated Obs from the animals used for 
the recovery period experiments. The effect of low protein 
diet on osteoblasts was verified by our in vitro bone for-
mation assay and gene expression of osteogenic markers. 
These results were unexpected since all cell cultures were 
managed under the same experimental conditions, that is, 
equal serum concentration and all in osteogenic medium. 
We assumed that when isolated Obs return to normal pro-
tein levels in vitro, they would have similar osteogenic be-
havior. In contrast with our expectations, osteoblastic cells 
retained the in vivo bone-forming capacity. These striking 
results led us to the novel conclusion that the nutritional 
protein level is able to leave a molecular signature in these 
cells.
We, therefore, hypothesized that the observed osteogenic 
activity during the recovery period is potentially regulated by 
epigenetic mechanisms or differential expression of bone-re-
lated miRs. We selected four key genes that are master regu-
lators of osteoblastic differentiation and activation (Bmpr1a, 
Ptch1, Osx, and Igf1r)87 and Sirt1, a NAD-dependent 
deacetylase, which promotes osteogenic differentiation88 and 
its expression is affected by dietary protein.57 Specific-site 
DNA pyrosequencing analysis revealed no differences in 
methylation patterns of selected genomic loci in the promoter 
region of osteoblastic regulatory genes. However, other CpG 
rich regions may be affected and this possibility needs further 
study. On the contrary, we found differential expression of 
miRs −26a, −34a, and −125b, which have been shown to 
regulate bone-related genes. MiR-125b regulates the osteo-
genic differentiation of human MSCs by targeting BMPR1b63 
while miR-26a reverses the bone regeneration deficit of 
MSCs,89 and miR-34a inhibits osteoclastogenesis.62 In ad-
dition, Bglap and Osx are directly targeted by miR-125b,90 
while downregulation of its expression results in high levels 
of Vdr.91 Transfection of hBMSCs with miR-125b mimics 
induces decreased osteogenic differentiation with lower ex-
pression levels of Alp, Col1a1, and Bglap.92 Thus, elevated 
levels of miR-125b inhibit bone formation, which we also de-
scribe in this study. The results exploring the role of miR-34a 
in osteogenesis are contradictory. It has been shown that miR-
34a overexpression results in increased osteogenic differen-
tiation of hASCs93 and reduces the inhibition of osteogenic 
differentiation of murine MSCs by dexamethasone.94 On the 
contrary, downregulation of miR-34a diminishes arthritis and 
bone loss in mice.95 To explain these conflicting findings, 
the distinct cell attributes as well as the different osteogenic 
regulation in health and disease has to be taken into consid-
eration. Finally, miR-26a enhances angiogenesis-osteogen-
esis coupling and augments bone regeneration and repair.96 
Furthermore, it regulates osteogenic differentiation of ADSC 
by targeting Smad1, which mediates BMP signaling path-
way, resulting in increased levels of osteopontin.97 It is also 
of great interest that GSK3β and Smad1 has also emerged 
as predicted targets of miR-26a in BMSCs, which results in 
increased Wnt3a and, consequently, higher bone formation.60 
During the bone recovery period, the expression of these 
miRs was altered favoring suppression of bone formation in 
combination with elevated resorption that was profound in 
the Rec-LL mice. This effect can be driven by dietary pro-
tein content as the Rec-LN dams showed partially recovery. 
Based on these observations, we performed a bioinformatic 
analysis aiming to examine, which genes could be potential 
targets of the specific miRs, and which revealed regulatory 
pathways involved in important bone homeostatic mecha-
nisms. The main pathways affected appear to be the Wnt and 
IL-6 signaling pathways, and these have profound effects on 
osteoblasts and osteoclasts, respectively.98,99
This study shows for the first time that maternal protein 
undernutrition during gestation/lactation leads to bone recov-
ery retardation. We focused on the phenotypic description 
of our model by providing novel information on the skeletal 
morphology (microCT) and the major cellular events (histol-
ogy, in vitro). Our data indicate that maternal protein intake 
and lactation-induced bone loss may be regulated by changes 
in miR expression. MiRs have shown long lasting effects in 
various pathologies and have been also established as poten-
tial biomarkers in bone disorders such as osteoporosis.100,101 
However, this work is not without limitations. While we have 
shown that bone formation is compromised in low protein 
fed dams, a detailed molecular/cellular mechanism underly-
ing remains to be unraveled. Furthermore, we anticipate ver-
ifying our bioinformatic approach for miRs both in vitro and 
in vivo. Next generation sequencing using Whole Genome 
Bisulfite Sequence, ChIP-seq, and small-RNA seq can be of 
great value to decipher a possible nutriepigenetic mechanism.
In conclusion, here, we report that low protein intake 
during the reproduction period does not affect the skeletal 
muscles and associated NMJs in mouse dams. However, 
protein under-nutrition increases lactation-induced bone 
loss, and maintenance on low protein diet during the recov-
ery period delays bone restoration. We provide strong evi-
dence to support our dual conclusion drawn by this study: 
a low protein diet decreases not only the total amount of 
cells with osteoblastic properties, but also the osteogenic 
potential of bone-forming cells. Importantly, isolated os-
teoblasts show similar in vitro osteogenic behavior to the 
in vivo findings, suggesting a possible epigenetic mecha-
nism. This dietary protein-dependent effect on bone metab-
olism might be controlled by changes in the expression of 
specific miRs. Further studies are required to identify the 
mechanism(s) underlying these effects of low protein diet. 
A full understanding of the mechanisms would be expected 
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to lead to improved nutritional guidelines during repro-
duction and could identify new targets for the treatment of 
musculoskeletal disorders.
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